Efavirenz +/- rifampicin +/- isoniazid in volunteers with CYP2B6 516 GG TT polymorphisms

Trial Profile

Efavirenz +/- rifampicin +/- isoniazid in volunteers with CYP2B6 516 GG TT polymorphisms

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2013

At a glance

  • Drugs Efavirenz (Primary) ; Isoniazid/rifampicin; Rifampicin
  • Indications HIV infections; Tuberculosis
  • Focus Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 11 Apr 2013 New trial record
    • 06 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top